Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 601 to 610 of 2591 total matches.
Viltolarsen (Viltepso) for Duchenne Muscular Dystrophy
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
oligonucleotide golodirsen
(Vyondys 53) was approved in 2019.1
Pronunciation Key
Viltolarsen: vil” toe lar’ sen ...
The antisense oligonucleotide viltolarsen (Viltepso –
NS Pharma) has received accelerated approval
from the FDA for treatment of Duchenne muscular
dystrophy (DMD) in patients who have mutations of the
dystrophin gene that are amenable to exon 53 skipping
(DMD-53). It is the second drug to be approved for this
indication; the antisense oligonucleotide golodirsen
(Vyondys 53) was approved in 2019.
Two New Doses of Dulaglutide (Trulicity) for Diabetes
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
Two New Doses of Dulaglutide
(Trulicity) for Diabetes
Table 1. Results of AWARD-111
A1C Change ...
The FDA has approved two additional doses (3 mg
and 4.5 mg) of the glucagon-like peptide-1 (GLP-1)
receptor agonist dulaglutide (Trulicity – Lilly) for
treatment of type 2 diabetes in adults. Dulaglutide has
been available in 0.75- and 1.5-mg doses for years.
A New Indication for Esketamine Nasal Spray (Spravato)
The Medical Letter on Drugs and Therapeutics • Sep 21, 2020 (Issue 1607)
for
treatment-resistant depression,1 has now been
approved for treatment of depressive symptoms in
adults ...
Esketamine (Spravato – Janssen), an intranasal
N-methyl-D-aspartate (NMDA) receptor antagonist
that was previously approved by the FDA for treatmentresistant
depression,1 has now been approved for
treatment of depressive symptoms in adults with
major depressive disorder (MDD) and acute suicidal
ideation or behavior. Esketamine is the S-enantiomer
of the anesthetic ketamine (Ketalar, and generics).
It is the first drug to be approved for this indication.
Most clinical trials of antidepressants have excluded
patients with acute suicidal ideation.
In Brief: Canagliflozin and Lower Limb Amputations
The Medical Letter on Drugs and Therapeutics • Sep 21, 2020 (Issue 1607)
of the drug.1 Package
inserts for canagliflozin products still contain a standard
warning about a risk ...
The FDA has removed a boxed warning from the labeling
of products containing the sodium-glucose co-transporter
2 (SGLT2) inhibitor canagliflozin (Invokana, Invokamet,
Invokamet XR) that described an increased risk of lower
limb amputation associated with use of the drug. Package
inserts for canagliflozin products still contain a standard
warning about a risk of lower limb amputation.
Table: Correct Use of Inhalers for COPD (online only)
The Medical Letter on Drugs and Therapeutics • Sep 07, 2020 (Issue 1606)
a click is heard, the inhaler is ready
to use
The dose indicator should count down by 1
Exhale fully ...
View the Table: Correct Use of Inhalers for COPD
Cenobamate (Xcopri) for Focal Seizures
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
be tried as monotherapy before
considering use of two drugs concurrently.1 Despite
the availability ...
The FDA has approved cenobamate (Xcopri – SK Life
Science) for oral treatment of partial-onset (focal)
seizures in adults.
Phexxi - A Nonhormonal Contraceptive Gel
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
), but
was never marketed.1
Phexxi — A Nonhormonal
Contraceptive Gel
CHOICE OF CONTRACEPTIVES — Intrauterine ...
The FDA has approved Phexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for on-demand
contraception; it is not effective when used
after intercourse. It was previously approved for
use as a vaginal lubricant (Amphora), but was never
marketed.
Ozanimod (Zeposia) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple ...
The FDA has approved ozanimod (Zeposia – Celgene),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple
sclerosis (MS), including clinically isolated syndrome
(initial neurological episode), relapsing-remitting
disease, and active secondary progressive MS
(SPMS). It is the third oral S1P receptor modulator to
be approved in the US for treatment of relapsing forms
of MS; siponimod (Mayzent) is also indicated for use
in adults, and fingolimod (Gilenya) is approved for use
in patients ≥10 years old.
IV Artesunate for Severe Malaria
The Medical Letter on Drugs and Therapeutics • Aug 10, 2020 (Issue 1604)
in children and adults. It has been available
from the CDC on a compassionate use basis since
2007.1 ...
Artesunate for injection (Amivas LLC), a semi-synthetic
artemisinin derivative, is now approved
by the FDA for initial (induction) treatment of severe
malaria in children and adults. It has been available
from the CDC on a compassionate use basis since
2007. Artemether/lumefantrine (Coartem), another
artemisinin-based drug, was approved earlier for oral
treatment of uncomplicated Plasmodium falciparum
malaria. IV artesunate is now the only FDA-approved
injectable antimalarial drug available in the US; IV
quinidine has been discontinued.
Drugs Past Their Expiration Date
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020 (Issue 1603)
on the label. Since our last article on this
subject,1 more data have become available.
SAFETY ...
Healthcare providers are often asked if drugs can
be used past their expiration date. Because of legal
restrictions and liability concerns, manufacturers do
not sanction such use and usually do not comment
on the safety or effectiveness of their products beyond
the date on the label. Since our last article on this
subject, more data have become available.